Form 4: Bolt Biotherapeutics CFO Acquires 235,000 Stock Options

William P. Quinn, CFO of Bolt Biotherapeutics, acquired 235,000 stock options on March 4, 2024, according to a Form 4 filing with the SEC.

Summary

• William P. Quinn, the Chief Financial Officer of Bolt Biotherapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports that Mr. Quinn acquired 235,000 stock options on March 4, 2024.
• The exercise price of these options is $1.27.
• The options vest monthly, with 1/36th of the shares vesting for each month of continuous service after January 1, 2024, provided Mr. Quinn continuously provides services to the Issuer.
• The options expire on March 3, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a standard SEC filing related to executive compensation. It's common for companies, especially in the biotech industry, to grant stock options to their executives as part of their compensation packages.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their executives.
• The vesting schedule of 1/36th per month is a common vesting structure.

Stakeholder Impact

• The granting of stock options aligns the CFO's interests with those of the shareholders, as the value of the options increases if the company's stock price increases.

Key Dates